Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Response Genetics Inc (OTCQB:RGDX)

0.1175
Delayed Data
As of Aug 04
 0.00 / 0.00%
Today’s Change
0.08
Today|||52-Week Range
0.85
-62.89%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.7M

Company Description

Response Genetics, Inc. is a life sciences company, which is engaged in the research and development of clinical diagnostic tests for cancer. It has developed technologies for the extraction of Ribonucleic acid (RNA) from formalin-fixed and paraffin-embedded tissues which enables to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics and microarray platforms. The company's platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. It also provides pharmacogenomic testing services of clinical trial specimens to pharmaceutical companies. The company was founded by David A. Smith and Kathleen Danenberg on September 23, 1999 and is headquartered in Los Angeles, CA.

Contact Information

Response Genetics, Inc.
1640 Marengo Street
Los Angeles California 90033-1036
P:(323) 224-3900
Investor Relations:

Employees

Shareholders

Individual stakeholders44.92%
Other institutional26.24%
Mutual fund holders1.90%

Top Executives

Thomas A. BolognaChairman & Chief Executive Officer
Kevin Roy HarrisChief Financial Officer & Vice President
Gary ZegerMedical Director
Alan CheeksVice President-Laboratory Operations
Eric ChenVice President-Business Development